Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

275

HTML

1948

Figures (1-1)

203

Tables (1-7)

213

Sum=2639

Nov 21, 2006 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Nov 21, 2006; 12(43): 6955-6960
Published online Nov 21, 2006. doi: 10.3748/wjg.v12.i43.6955

Table 4 Comparison of thalidomide treatment and survival between the two groups

¹Partial response;

²Stable disease;

³Progressive disease;

^aP < 0.05,

^cP < 0.05 vs duration, between the two groups.

Citation: Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(43): 6955-6960
URL: https://www.wjgnet.com/1007-9327/full/v12/i43/6955.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i43.6955